# Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept

> **NCT02615496** · — · COMPLETED · sponsor: **Bayer** · enrollment: 716 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **BEHAVIORAL:** Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- **BEHAVIORAL:** Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

## Key facts

- **NCT ID:** NCT02615496
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-07
- **Primary completion:** 2016-09-30
- **Final completion:** 2017-01-31
- **Target enrollment:** 716 (ACTUAL)
- **Last updated:** 2017-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02615496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02615496, "Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02615496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*